Gemcitabine and oxaliplatin combination in patients with advanced adrenocortical carcinoma
Journal of the Endocrine Society · 08.07.2026 · 10 (8)
DOI: 10.1210/jendso/bvag152 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Endocrine Society, online erschienen am 01.07.2026. Verfasst von Lily Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Context
Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with limited treatment options beyond first-line therapy, underscoring the need for effective salvage regimens.
Objective
To evaluate the clinical activity and safety of gemcitabine and oxaliplatin (GemOx) in advanced ACC.
Design
Retrospective cohort study conducted from April 2023 to April 2024 with longitudinal follow-up.
Setting
Single-center tertiary referral cancer center. Patients or Other Participants Fourteen patients with histologically confirmed advanced ACC treated with GemOx were included. Patients were heavily pretreated, with a median of 3 prior systemic therapies (range, 2-9); 43% had hormonally functional tumors. Intervention(s) Gemcitabine (1000 mg/m2 on days 1 and 8) and oxaliplatin (130 mg/m2 on day 1) every 3 weeks until disease progression or unacceptable toxicity. Main Outcome Measure(s) Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included objective response rate per Response Evaluation Criteria In Solid Tumors 1.1 and treatment-related toxic effects.
Results
After a median follow-up of 10.7 months (95% CI, 8.5-15.7), median PFS was 3.2 months (95% CI, 0.4-6.0) and OS was 13.0 months (95% CI, 3.6-22.5). Among 13 evaluable patients, 2 (15.4%) achieved partial response, 8 (61.5%) had stable disease, and 3 (23.1%) had progressive disease, yielding a disease control rate of 76.9%. No treatment-related deaths occurred.
Conclusion
GemOx demonstrated modest clinical activity with manageable safety in heavily pretreated patients with advanced ACC. These findings suggest a potential role for GemOx as a salvage option, though validation in larger prospective studies is needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
- Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
ORCID-Profile: Lily Chen, Vania Balderrama-Brondani, Camilo Jimenez, Matthew T Campbell
Zitieren
APA
Chen, L., Balderrama-Brondani, V., Marcal, L. P., Jimenez, C., Varghese, J., Shah, A. Y., Habra, M. A., & Campbell, M. T. (2026). Gemcitabine and oxaliplatin combination in patients with advanced adrenocortical carcinoma. Journal of the Endocrine Society, 10(8). https://doi.org/10.1210/jendso/bvag152
Vancouver
Chen L, Balderrama-Brondani V, Marcal LP, Jimenez C, Varghese J, Shah AY, et al. Gemcitabine and oxaliplatin combination in patients with advanced adrenocortical carcinoma. Journal of the Endocrine Society. 2026;10(8). doi:10.1210/jendso/bvag152
BibTeX
@article{Chen2026,
author = {Chen, Lily and Balderrama-Brondani, Vania and Marcal, Leonardo P and Jimenez, Camilo and Varghese, Jeena and Shah, Amishi Y and Habra, Mouhammed Amir and Campbell, Matthew T},
title = {Gemcitabine and oxaliplatin combination in patients with advanced adrenocortical carcinoma},
journal = {Journal of the Endocrine Society},
year = {2026},
volume = {10},
number = {8},
doi = {10.1210/jendso/bvag152}
}
EUVIMED